Core Insights - Catheter Precision, Inc. has entered into a strategic distribution agreement with FuMedica AG to introduce its LockeT suture retention device in Switzerland [1][4] - The LockeT device is designed to simplify and secure the closure of vascular access sites after cardiac procedures, enhancing procedural outcomes [2][5] - FuMedica AG is recognized for its excellence in distributing advanced medical technologies, particularly in cardiology, making it a suitable partner for Catheter Precision [3][7] Company Overview - Catheter Precision is a U.S.-based medical device company focused on innovative solutions for cardiac arrhythmias and electrophysiology procedures [6] - The company aims to improve treatment outcomes through collaboration with physicians and continuous product advancement [6] Product Details - The LockeT device is classified as a Class 1 medical device registered with the FDA and has received CE Mark approval, indicating its compliance with European health standards [5] - Its intuitive design and reliable performance have made it a valuable tool in electrophysiology labs and interventional suites globally [2] Partnership Significance - The agreement with FuMedica AG is a key milestone in Catheter Precision's European growth strategy, leveraging FuMedica's market knowledge and commitment to quality [4] - The partnership reflects Catheter Precision's dedication to global collaboration and innovation in cardiac care [4]
Catheter Precision Enters Distribution Agreement with FuMedica AG to Bring LockeT to Switzerland